- The FDA has signed off Monopar Therapeutics Inc's MNPR IND to commence an open-label Phase 1b dose-escalation trial to evaluate camsirubicin plus pegfilgrastim in patients with advanced soft tissue sarcoma (ASTS).
- Enrollment will start in Q4 of 2021.
- "Camsirubicin is a novel analog of doxorubicin, and doxorubicin is known to work through a dose-dependent mechanism, where higher quantities yield more anti-cancer effect," said Andrew Mazar, Monopar's Chief Scientific Officer.
- Price Action: MNPR shares are up 6.77% at $5.68 during the premarket session on the last check Tuesday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
